Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.
Keyword(s):
Phase I
◽
2019 ◽
Vol 25
(17)
◽
pp. 5212-5220
◽